Which combination therapy is best for newly diagnosed myeloma patients? This randomized phase III study compares bortezomib, lenalidomide and dexamethasone (RVd) with carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed patients. Both options are considered "standard of care" treatments for newly diagnosed multiple myeloma. This study is open at 21 different locations in Wisconsin. Click here to learn more: Newly Diagnosed Myeloma Clinical Trial